Hepatic angiomyolipoma

Summary

Hepatic angiomyolipoma (MONDO:0002605) is a disease. A subtype of angiomyolipoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	hepatic angiomyolipoma
Mondo ID	MONDO:0002605
DOID	DOID:3317
NCIT	C27485
UMLS	C1333962
MedGen	272705
GARD	0023185
Anatomy (UBERON)	UBERON:0002107
Is cancer (heuristic)	no

Also known as: liver angiomyolipoma · liver PEComa

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › connective and soft tissue neoplasm › soft tissue neoplasm › neoplasm with perivascular epithelioid cell differentiation › angiomyolipoma › hepatic angiomyolipoma

Related subtypes (2): epithelioid type angiomyolipoma, kidney angiomyolipoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.